HIV clinical trial design for antiretroviral development: Moving forward

AIDS

Volumn 22, Issue 18, 2008, Pages 2419-2427

  Chan Tack, Kirk M ^a   Struble, Kimberly A ^a   Morgensztejn, Nathalie ^b   Murray, Jeffrey S ^a   Gulick, Roy ^c   Cheng, Ben ^d   Weller, Ian ^e   Miller, Veronica ^d,f  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b EUROPEAN MEDICINES AGENCY   (United Kingdom)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Forum for Collaborative HIV Research   (United States)

Author keywords

Antiretroviral therapy; Clinical trial design; HIV 1; Noninferiority; Optimized background regimen; Salvage therapy; Treatment experienced; Treatment naive

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTIRETROVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTEGRASE INHIBITOR; MARAVIROC; METHADONE; PLACEBO; RALTEGRAVIR;

BONE DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL STUDY; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG APPROVAL; DRUG EFFICACY; DRUG PROGRAM; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; EDITORIAL; GASTROINTESTINAL TOXICITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; METABOLIC DISORDER; METHODOLOGY; MITOCHONDRIAL TOXICITY; OPEN STUDY; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESEARCH ETHICS; TERATOGENICITY; UNSPECIFIED SIDE EFFECT;

ANTI-RETROVIRAL AGENTS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION; DRUG MONITORING; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; RESEARCH DESIGN;

EID: 57549085564     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32831692e6     Document Type: Editorial

References (36)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents - 29 January 2008; 1-128. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf. [Accessed 29 June 2008].
2. EMEA/CHMP Guideline on the Clinical Development of Medicinal Products for the Treatment of HIV Infection, http://emea.europa.eu/pdfs/human/ewp. [Accessed 29 June 2008].
3. Gazzard B, Bernard AJ, Boffito M, Churchill D, Edwards S, Fisher N, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2008). www.bhiva.org. [Accessed 29 June 2008].
4. Feinberg J, Japour AJ. Scientific and ethical considerations in trial design for investigational agents for the treatment of human immunodeficiency virus infection. Clin Infect Dis 2003;36:201-206.
5. Struble K, Murray J, Cheng B, Gegeny T, Miller V, Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS 2005;19:747-756.
6. De Gruttola V, Flexner C, Schapiro J, Hughes M, Van Der Laan M, Kuritzkes D. Drug development strategies for salvage therapy: conflicts and solutions. AIDS Res Hum Retroviruses 2006;22:1106-1109.
7. Mayers D, Chung J, Kohlbrenner V, Hall D, DeMasi R, Neubacher D, et al. Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective. AIDS Res Hum Retroviruses 2006;22:1110-1112.
8. Lederman M, Miller V, Weller I, Deeks S. A new approach for 'deep salvage' trials in advanced HIV infection. AIDS 2007;21:1503- 1506.
9. Nelson M, Arastéh K, Clotet B, Cooper D, Henry K, Katlama C, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-412.
10. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178.
11. Hicks C, Cahn P, Cooper D, Walmsley S, Katlama C, Clotet B, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-475.
12. Maraviroc. New London, CT: Pfizer; August 2007 (package insert).
13. Food and Drug Administration. Antiviral Drugs Advisory Committee Briefing Document (24 April 2007) - Maraviroc. http://www.fda.gov/OHRMS/ DOCKETS/AC/07/briefing/2007-4283b1-01-Pfizer.pdf. [Accessed 29 June 2008].
14. Raltegravir. Whitehouse Station, NJ: Merck; October 2007 (package insert).
15. Steigbigel R, Cooper D, Kumar P, Eron J, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-354.
16. Cooper D, Steigbigel R, Gatell J, Rockstroh J, Katlama C, Yeni P, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-365.
17. Etravirine. Raritan, NJ: Tibotec; January 2008 (package insert).
18. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet 2007;370:29-38.
19. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebocontrolled trial. Lancet 2007;370:39-48.
20. Towner W, Haigney Z, Sension MG, Wohlfeiler M, Gathe J, Applebaum JS, et al. Efficacy, safety and tolerability of etravirine with and without darunavir and/or raltegravir in treatment-experienced patients: preliminary analysis of TMC125-C214 (early access program) [abstract TUPE0066]. XVII International AIDS Conference; August 2008; Mexico City.
21. Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, et al. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitorexperienced HIV-1-infected subjects. J Infect Dis 2004;190: 886-893.
22. Hatano H, Hunt P, Weidler J, Coakley E, Hoh R, LieglerT, et al. Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006;43:1329- 1336.
23. Sax PE. Therapeutic options for treatment experienced patients: a focus on resistance testing and optimizing background therapy. AIDS Read 2006;16:265-275; 277-278.
24. Montaner J, Guimaraes D, Chung J, Gafoor Z, Salgo M, DeMasi R. Prognostic staging of extensively pretreated patients with advanced HIV-1 disease. HIV Clin Trials 2005;6:281-290.
25. Maggiolo F, Airoldi M, Callegaro A, Ripamonti D, Gregis G, Quinzan G, et al. Prediction of virologic outcome of salvage antiretroviral treatment by different systems for interpreting genotypic HIV drug resistance. J Int Assoc Physicians AIDS Care 2007;6:87-93.
26. Forum for Collaborative HIV Research. Standardization and Clinical Relevance of HIV Drug Resistance Testing. http://www.hivforum.org/projects/ standardization.html. [Accessed 29 June 2008].
27. Tsong Y, Levenson M, Zhang J, Zhong J. Choice of lambdamargin and dependency of noninferiority trials. Stat Med 2008;27:520-528.
28. Food and Drug Administration. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements - clinical considerations for accelerated and traditional approval (October 2002). http://www.fda.gov/ cder/guidance/3647fnl.htm. [Accessed 22 August 2008].
29. Boffito M, Winston A, Jackson A, Fletcher C, Pozniak A, Nelson M, et al. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 2007;21:1449-1455.
30. Forum for Collaborative HIV Research. Rethinking the Approach to Expanded Access Programs. http://www.hivforum.org/uploads/EAP/ EAP%20Final%20Report3.pdf. [Accessed 29 June 2008].
31. Amorosa V, Tebas P. Is it time to rethink the expanded access programs for HIV infection? J Infect Dis 2007;196:974-977.
32. Molina JM, Cohen C, Katlama C, Grinsztejn B, Timerman A, Pedro Rde J, et al. The safety and efficacy of darunavir with lowdose ritonavir in treatment-experienced patients: 24 week results of POWER 3. J Acquir Immune Defic Syndr 2007;46:24-31.
33. Thal G, Maa J, McManus M, Bessen L, Abrams L, Cooney E, etal. Improvement in hyperlipidemia following switch of antiretroviral (ARV) therapy to an atazanavir-based HAART regimen: experience from the U.S. Atazanavir Early Access Program (EAP) [abstract WePeB5906]. In: XV International AIDS Conference; July 2004; Bangkok.
34. Gallant JE, Rodriguez AE, Weinberg WG, Young B, Berger DS, Lim ML, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005;192:1921-1930.
35. Blanchard JN, Wohlfeiler M, Canas A, King K, Lonergan JT. Pancreatitis with didanosine and tenofovir disoproxil fumarate. Clin Infect Dis 2003;37:e57-e62.
36. Saag M, Ive P, Heera J, Tawadrous M, DeJesus E, Clumeck N, et al. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDVJ/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV-1: week 48 results of the MERIT study [abstract WESS104], In: 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney.